Medicare rules, CMS guidance, reimbursement, and benefit changes affecting patients and providers.
Starting July 1, 2026, Medicare begins a temporary “GLP-1 Bridge” for some people with Medicare Part D. Eligible beneficiaries can get certain weight-loss GLP-1 drugs for a predictable $50 copay per month through Dec. 31, 2027—through a pathway that doesn’t work like standard Part D cost-sharing (including how TrOOP, deductibles, and low-income subsidy work).
Starting April 1, 2026, CMS begins enforcing updated hospital price transparency rules. The changes include new allowed-amount fields in hospitals’ machine-readable files and updated attestation/identifier requirements. Medicare beneficiaries can use the posted “shoppable services” data to compare scheduled outpatient care—but the figures are not a personalized Medicare out-of-pocket estimate.
CMS’s proposed CY 2027 Hospital OPPS/ASC rule would adjust Medicare hospital outpatient payments for certain 340B-acquired drugs, change how some outpatient imaging is paid (including rural Sole Community Hospital exemptions), and continue the phase-out of the Inpatient Only (IPO) list. CMS also issued an RFI to improve hospital price-transparency data. The proposal is not final; comments are due August 31, 2026.
Starting July 1, 2026, Medicare began a temporary GLP-1 Bridge that can cover certain weight-loss drugs for a $50 monthly copay. But the program is narrower than many people expect, and the $50 does not work like regular Part D cost-sharing.
Starting July 1, 2026, some Medicare Part D enrollees may get Wegovy or Zepbound for weight loss through CMS’s temporary GLP-1 Bridge, but it is not broad standard Medicare coverage.
The 2026 Medicare Trustees Report says Medicare Part A’s hospital trust fund could be depleted in 2033. Here’s what that does — and does not — mean for beneficiaries right now.
CMS’s new Medicare GLP-1 Bridge starts July 1, 2026, but it is not broad new obesity-drug coverage for everyone. Here is who may qualify, which drugs and uses are included, and what the $50 monthly price does not count toward under Part D.
CMS released the 2026 Medicare premium and deductible amounts on Nov. 14, 2025, and the changes can affect what many beneficiaries pay this year. The biggest updates are in Original Medicare, but total costs can still differ by plan, especially in Medicare Advantage and Part D.
CMS began enforcing updated hospital price transparency requirements on April 1, 2026. The changes are meant to make hospital pricing files clearer and more useful, but they still do not guarantee an easy-to-understand final bill.
CMS has put a six-month nationwide pause on new Medicare enrollment for hospices and home health agencies. Existing providers can keep serving patients, and current Medicare coverage does not change, but families choosing a new agency may face tighter screening and fewer new entrants while CMS says it works to curb fraud.
CMS and the FDA have created a new Medicare coverage pathway aimed at speeding access to certain breakthrough medical devices. The first practical effect is a faster route to a proposed Medicare coverage decision after FDA authorization, but many details still depend on implementation.
CMS has proposed a rule that would extend electronic prior authorization to certain drugs covered under a medical benefit. It would not take effect right away, and most patients would not feel the change until at least 2027 if the rule is finalized.
CMS says it began enforcing updated hospital price transparency rules on April 1, 2026, but patients should still treat posted prices as a starting point.
Original Medicare can pay for some hearing tests in 2026, but hearing aids are still usually excluded. Here is what changed, what did not, and what to compare.
As of April 1, 2026, CMS is enforcing updated hospital price transparency rules. The files may be easier to compare, but they still are not your final bill.
Current U.S. guidance says adults 75 and older who have never had an RSV shot should get one dose now, with no repeat dose advised at this time.
A new Medicare study suggests the $35 insulin cap is lowering patients’ costs. But supplies, other diabetes expenses, and gaps outside Medicare still matter.
A new CMS proposal could close a pathway for states to add adult dental benefits to ACA Marketplace plans in 2027, leaving many shoppers with separate coverage.
A knee arthritis study points to real symptom relief with semaglutide, but Medicare access still depends on why it is prescribed and who qualifies.
As of April 2026, the federal nursing home staffing rule is no longer being phased in. Here’s what it would have required and what families should watch now.
Medicare’s 2026 physician payment rule may improve care coordination, telehealth, and home visits, but local staffing and practice finances still matter.
Some plans now have to post 2025 prior-authorization data. Here is what patients and clinicians can learn from the new CMS reports, and what they cannot.
End of content
End of content
